Evidence map›Paper›PMID 37207227›Full record

ArticleFrontiers in immunology2023

Efficient

Sandra Dross, Rasika Venkataraman, Shabnum Patel, Meei-Li Huang, Catherine M Bollard, Margherita Rosati, George N Pavlakis, Barbara K Felber, Katharine J Bar, George M Shaw and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

Sandra DrossDepartment of Microbiology, University of Washington, Seattle, WA, United States.
Rasika VenkataramanDivision of Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Shabnum PatelCenter for Cancer and Immunology Research, Children's National Hospital and Department of Pediatrics, The George Washington University, Washington, DC, United States.
Meei-Li HuangDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States.
Catherine M BollardCenter for Cancer and Immunology Research, Children's National Hospital and Department of Pediatrics, The George Washington University, Washington, DC, United States.
Margherita RosatiHuman Retrovirus Section, Vaccine Branch, National Cancer Institute at Frederick, Frederick, MD, United States.
George N PavlakisHuman Retrovirus Section, Vaccine Branch, National Cancer Institute at Frederick, Frederick, MD, United States.
Barbara K FelberHuman Retrovirus Pathogenesis Section, Vaccine Branch, National Cancer Institute at Frederick, Frederick, MD, United States.
Katharine J BarPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
George M ShawPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Keith R JeromeDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States.
James I MullinsDepartment of Microbiology, University of Washington, Seattle, WA, United States.
Hans-Peter KiemWashington National Primate Research Center, Seattle, WA, United States.
Deborah Heydenburg FullerDepartment of Microbiology, University of Washington, Seattle, WA, United States.
Christopher W PetersonDivision of Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Frederick National Laboratory for Cancer Research · USOregon National Primate Research Center · USUniversity of Washington · USGeorge Washington University Hospital · USUniversity of Pennsylvania · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAFred Hutch Cancer Center · US

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
WaNPRC Macaca nemestrina SPF Breeding ColonyU42OD011123 · OD · UNIVERSITY OF WASHINGTON · PI CHARLOTTE HOTCHKISS · 2012 to 2026
$34.4M
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral EradicationUM1AI126617 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD, NIXON, DOUGLAS F · 2016 to 2020
$28.1M
Cell and Gene Therapy for HIV CureUM1AI126623 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI JEROME, KEITH R, KIEM, HANS-PETER · 2016 to 2020
$24.2M
Posttranscriptional control of gene expressionZIABC010334 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FELBER, BARBARA K · 2009 to 2025
$15.1M
Novel macrophage-tropic transmitted/founder SHIV model of CNS persistence to evaluate CRISPR/Cas9 gene editingR01MH128155 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI BAR, KATHARINE JUNE, BURDO, TRICIA HELEN · 2021 to 2025
$4.7M
In Vivo Gene Editing of B cells with NICE-AAV VectorsR01AI167004 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Christopher W Peterson · 2022 to 2026
$3.7M
Developing Durable, Env-Boosted CAR T Cells for HIV CureR01AI170214 · NIAID · FRED HUTCHINSON CANCER CENTER · PI Christopher W Peterson · 2023 to 2026
$3.4M
Determining the effects of broadly neutralizing antibodies at antiretroviral therapy initiationR01AI179666 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Katharine June Bar, Mirko Paiardini · 2023 to 2026
$3.4M
Reverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine DesignR01AI160607 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2021 to 2024
$3.2M
NIAID NIH HHS R01 AI160607NIAID NIH HHS R01 AI167004NIAID NIH HHS R01 AI170214NIAID NIH HHS R01 AI179666NIAID NIH HHS UM1 AI126617NIAID NIH HHS UM1 AI126623NIH HHS P51 OD010425NIH HHS U42 OD011123NIMH NIH HHS R01 MH128155
6 · The paper itself

Abstract

HIV-specific T cells are necessary for control of HIV-1 replication but are largely insufficient for viral clearance. This is due in part to these cells' recognition of immunodominant but variable regions of the virus, which facilitates viral escape

Indexed as

HIV-1HIV InfectionsSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusVaccinesAnimalsCD8-Positive T-LymphocytesHumansMacaca mulattaVaccinesantigen-specific T cellscell therapiesDNA vaccineHIV-1 curenonhuman primate modelsrhesus macaquetherapeutic vaccines

Identifiers

PMID37207227
PMCPMC10189133
OpenAlexW4367845079

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.